Journey Medical expands Emrosi payer coverage to ~85% of US commercial lives after third GPO contract

Journey Medical Corp

Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.
Approximately 85% of all US commercial lives now have access to Emrosi for treatment of inflammatory rosacea lesions.
CEO cites milestone for Emrosi launch; expects less reliance on copay bridging and improved profitability as formulary adoption grows.
Focus remains on converting access into coverage through health plan formulary adoption throughout 2026 and beyond.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.